AllianceBernstein
CRNX

AllianceBernstein’s Crinetics Pharmaceuticals CRNX Stock Holding History

AllianceBernstein’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.78M Sell
131,680
-39,269
-23% -$1.46M ﹤0.01% 1574
2026
Q1 		$7.96M Buy
170,949
+77,929
+84% +$3.48M ﹤0.01% 1311
2025
Q4 		$4.33M Hold
93,020
– – ﹤0.01% 1611
2025
Q3 		$3.87M Hold
93,020
– – ﹤0.01% 1643
2025
Q2 		$2.68M Sell
93,020
-17,654
-16% -$545K ﹤0.01% 1787
2025
Q1 		$3.71M Buy
110,674
+8,954
+9% +$334K ﹤0.01% 1576
2024
Q4 		$5.2M Buy
101,720
+9,190
+10% +$514K ﹤0.01% 1471
2024
Q3 		$4.73M Hold
92,530
– – ﹤0.01% 1538
2024
Q2 		$4.14M Buy
92,530
+25,260
+38% +$1.17M ﹤0.01% 1565
2024
Q1 		$3.15M Hold
67,270
– – ﹤0.01% 1669
2023
Q4 		$2.39M Buy
67,270
+6,130
+10% +$188K ﹤0.01% 1840
2023
Q3 		$1.82M Buy
61,140
+9,940
+19% +$205K ﹤0.01% 1927
2023
Q2 		$923K Hold
51,200
– – ﹤0.01% 2322
2023
Q1 		$822K Hold
51,200
– – ﹤0.01% 2321
2022
Q4 		$937K Hold
51,200
– – ﹤0.01% 2319
2022
Q3 		$1.01M Hold
51,200
– – ﹤0.01% 2286
2022
Q2 		$955K Buy
51,200
+21,600
+73% +$431K ﹤0.01% 2371
2022
Q1 		$650K Buy
29,600
+100
+0.3% +$2.02K ﹤0.01% 2567
2021
Q4 		$838K Hold
29,500
– – ﹤0.01% 2535
2021
Q3 		$621K Hold
29,500
– – ﹤0.01% 2673
2021
Q2 		$556K Buy
29,500
+2,700
+10% +$47.4K ﹤0.01% 2773
2021
Q1 		$410K Sell
26,800
-1,100
-4% -$17K ﹤0.01% 2758
2020
Q4 		$394K Buy
27,900
+2,000
+8% +$27.9K ﹤0.01% 2706
2020
Q3 		$406K Hold
25,900
– – ﹤0.01% 2642
2020
Q2 		$454K Buy
25,900
+11,100
+75% +$189K ﹤0.01% 2676
2020
Q1 		$218K Buy
14,800
+3,000
+25% +$61.5K ﹤0.01% 2760
2019
Q4 		$296K Buy
11,800
+600
+5% +$11.4K ﹤0.01% 2780
2019
Q3 		$168K Buy
11,200
+2,200
+24% +$42.8K ﹤0.01% 2980
2019
Q2 		$225K Buy
+9,000
New +$223K ﹤0.01% 2925

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein's CRNX Position: Q2 2026 in Review

AllianceBernstein reduced its Crinetics Pharmaceuticals (CRNX) stake by 23% in Q2 2026, selling an estimated $1.46M and leaving 131,680 shares worth $4.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1574.

AllianceBernstein first reported a position in CRNX in Q2 2019 and has held it in 29 quarters since. The position peaked at $7.96M in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • AllianceBernstein held 131,680 shares of Crinetics Pharmaceuticals worth $4.78M as of Q2 2026.
  • AllianceBernstein sold 39,269 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.46M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #1574 holding.
  • AllianceBernstein first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • AllianceBernstein's Crinetics Pharmaceuticals position peaked at $7.96M in Q1 2026.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.